Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: Chasing windmills?

Liver Transplantation

Volumn 12, Issue 9, 2006, Pages 1317-1319

  Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EPITOPE; GLYCOPROTEIN; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E2; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS RNA;

DRUG DOSE REGIMEN; EDITORIAL; HEPATITIS C; INFECTION PREVENTION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECURRENT INFECTION; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION;

EID: 33748806307     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20889     Document Type: Editorial

References (30)

1. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-1398.
2. Dienstag JL. Passive active immunoprophylaxis after percutaneous exposure to hepatitis B virus. Hepatology 1989; 10:385-387.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhsmou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
4. Organ Procurement and Transplantation Network (OPTN) database. Available at: http://www.optn.org. Accessed: February 15, 2005.
5. Wright TL, Donegan E, Hsu HH, Farrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317-322.
6. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8(10 suppl 1):S19-S27.
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
8. Krause RM, Dimmock NJ, Morens DM. Summary of anti-body workshop: the role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997;176:549-559.
9. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-1398.
10. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006;43:592-601.
11. Triyatni M, Vergalla. J, Davis AR, Hadlock KG, Foung SK, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 2002; 298:124-132.
12. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197:633-642.
13. Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 2002;76:9335-9344.
14. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the E2 protein. Proc Natl Acad Sci U S A 1996;93:15394-15399.
15. Keck ZY, Op De Beeck A, Hadlock KG, Ma J, Li TK, Dubuisson J, Foung SK. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 2004;78:9224-9232.
16. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994; 91:7792-7796.
17. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140.
18. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004;101:10149-10154.
19. Yu MW, Bartosch B, Zhang P, Guo ZP, Renzi PM, Shen LM, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 2004;101:7705-7710.
20. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Inf Dis 1996;173:822-828.
21. Willems B, Ede M, Marotta P, Wall W, Greig P, Lilly L, et al. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J Hepatol 2002;36(suppl 1):32.
22. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11:941-949.
23. XTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12: 1381-1389.
24. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364.
25. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005:79:8400-8409.
26. Eren R, Landstein D, Terkieltaub D,et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006;80:2654-2664.
27. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Microbiol Immunol (Berl) 1993;182:329-334.
28. Prince AM, Huima-Byron T, Parker TS, Levine DM. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 1996;3:11-17.
29. Burioni R, Bugli F, Mancini N, Rosa D, Di Campli C, Moroncini G, et al. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 2001;288:29-35.
30. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006;80: 2418-2428.